文献速递其他结缔组织病

抗HMGCR免疫介导坏死性肌病患者靶组织中HMGCR反应性CD4+T细胞的精准鉴定与追踪

Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.
PubMed 文献 · Ann Rheum Dis · 2025-01-02

研究旨在鉴定抗HMGCR阳性免疫介导坏死性肌病患者中HMGCR反应性CD4+T细胞,并评估其在受累肌肉组织中的存在。结果显示,患者外周血CD4+T细胞对HMGCR蛋白及肽段反应增强,且反应性TCRβ基序在肌肉活检组织中富集,提示这些细胞在疾病发病机制中可能发挥积极作用。

要点

  • 抗HMGCR+IMNM患者CD4+T细胞对HMGCR蛋白反应高于DM患者(中位数0.06 vs 0.00,p=0.0059)。
  • 9/10抗HMGCR+IMNM患者对至少一种HMGCR肽段产生反应,DM为1/10(p=0.0003)。
  • HMGCR反应性TCRβ的抗原反应性基序在肌肉活检组织中富集(投影评分0.03 vs 0.63,p=0.007)。

主要发现

  • 抗HMGCR+IMNM患者CD4+T细胞对HMGCR蛋白的反应高于DM患者(中位数0.06 vs 0.00,p=0.0059)。
  • 这些反应富集于Th1-Th17细胞,且当存在时与抗HMGCR抗体水平正相关(r2=0.89,p=0.0012)。
  • NAPA揭示7个HMGCR核心肽段的汇聚呈递,患者间肽段谱有大量重叠。
  • 这些HMGCR肽段引发强烈的CD4+T细胞反应,9/10抗HMGCR+IMNM患者对至少一种肽段反应,DM为1/10(p=0.0003)。
  • HMGCR反应性TCRβ分析产生抗原反应性基序,在肌肉活检组织中富集(投影评分0.03 vs 0.63,p=0.007)。

关键数值与推荐

  • 抗HMGCR+IMNM患者CD4+T细胞对HMGCR蛋白反应中位数0.06,DM患者0.00(p=0.0059)。
  • 9/10抗HMGCR+IMNM患者对至少一种HMGCR肽段反应,DM为1/10(p=0.0003)。
  • HMGCR反应性TCRβ基序在肌肉活检组织中的投影评分0.63,对比0.03(p=0.007)。
  • CD4+T细胞对HMGCR蛋白反应与抗HMGCR抗体水平正相关(r2=0.89,p=0.0012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune-mediated necrotising myopathy (IMNM) is characterised by the presence of IgG autoantibodies against HMGCR and a strong association with specific HLA-DR alleles. Although these findings implicate HMGCR-specific CD4+T-cells in the disease's pathogenesis, no such cells have been described. In this study, we aimed to identify and characterise HMGCR-reactive CD4+T-cells and assess their presence in affected muscle tissue from patients with anti-HMGCR+IMNM. METHODS: Peripheral blood mononuclear cells from patients with anti-HMGCR+IMNM (n=10) and dermatomyositis (DM; n=10) were stimulated with HMGCR protein and peptides identified using a natural antigen processing assay (NAPA; n=6). CD4+T-cell activation was assessed by CD154 upregulation via flow cytometry. T-cell receptor β(TCR) sequencing was performed on paired HMGCR-reactive T-cells and muscle biopsy tissue (n=5). RESULTS: CD4+T-cell responses to HMGCR protein were higher in patients with anti-HMGCR+IMNM compared with DM (median 0.06 vs 0.00, p=0.0059). These responses were enriched in Th1-Th17 cells, and when present, they positively correlated with anti-HMGCR antibody levels (r2=0.89, p=0.0012). NAPA revealed convergent presentation of seven HMGCR core peptides, with substantial overlap in the peptide repertoires between patients. These HMGCR peptides elicited robust CD4+T-cell responses, with 9/10 anti-HMGCR+IMNM patients responding to at least one peptide, compared with 1/10 DM (p=0.0003). Analysis of HMGCR-reactive TCRs β yielded antigen-reactive motifs that were enriched in muscle biopsies (projection score 0.03 vs 0.63, p=0.007). CONCLUSION: HMGCR-antigen-reactive CD4+T-cells are present in the circulation and target tissue of patients with anti-HMGCR+IMNM, suggesting an active role for these cells in the pathogenesis of anti-HMGCR+IMNM.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Tiniakou E, Girgis A, Siafei T, et al. Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy. Ann Rheum Dis. 2025. PMID: 39919903. doi:10.1136/ard-2024-225732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。